ChronoScale Corporation Common Stock (NASDAQ:CHRN) Sees Significant Growth in Short Interest

ChronoScale Corporation Common Stock (NASDAQ:CHRN) was the recipient of a significant growth in short interest during the month of May. As of May 15th, there was short interest totaling 424,399 shares, a growth of 135.1% from the April 30th total of 180,534 shares. Approximately 12.8% of the company’s stock are short sold. Based on an average daily trading volume, of 420,857 shares, the days-to-cover ratio is currently 1.0 days.

ChronoScale Corporation Common Stock Stock Performance

CHRN traded up $0.07 on Friday, hitting $18.36. The company’s stock had a trading volume of 177,507 shares, compared to its average volume of 378,210. The firm has a market cap of $65.36 million, a P/E ratio of -3.41 and a beta of 0.86. ChronoScale Corporation Common Stock has a 12 month low of $2.73 and a 12 month high of $20.70. The company has a quick ratio of 1.03, a current ratio of 1.55 and a debt-to-equity ratio of 0.25. The company’s 50 day simple moving average is $12.34 and its 200-day simple moving average is $9.38.

ChronoScale Corporation Common Stock (NASDAQ:CHRN) last issued its earnings results on Tuesday, April 28th. The company reported ($2.04) EPS for the quarter, missing the consensus estimate of ($0.03) by ($2.01). The company had revenue of $2.14 million during the quarter, compared to the consensus estimate of $4.29 million. ChronoScale Corporation Common Stock had a negative return on equity of 197.81% and a negative net margin of 135.66%. Analysts forecast that ChronoScale Corporation Common Stock will post -0.1 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ChronoScale Corporation Common Stock in a research report on Friday, March 27th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, ChronoScale Corporation Common Stock has a consensus rating of “Reduce” and an average target price of $6.00.

Hedge Funds Weigh In On ChronoScale Corporation Common Stock

A number of institutional investors have recently added to or reduced their stakes in the business. Roble Belko & Company Inc boosted its position in shares of ChronoScale Corporation Common Stock by 104.5% during the 1st quarter. Roble Belko & Company Inc now owns 2,338 shares of the company’s stock valued at $25,000 after acquiring an additional 1,195 shares during the last quarter. Virtu Financial LLC bought a new position in shares of ChronoScale Corporation Common Stock in the third quarter worth approximately $57,000. Shay Capital LLC purchased a new stake in ChronoScale Corporation Common Stock in the third quarter valued at approximately $67,000. Geode Capital Management LLC raised its stake in ChronoScale Corporation Common Stock by 68.9% in the fourth quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock valued at $218,000 after purchasing an additional 10,281 shares in the last quarter. Finally, Citadel Advisors LLC bought a new stake in ChronoScale Corporation Common Stock during the third quarter valued at approximately $198,000. 6.42% of the stock is currently owned by institutional investors.

ChronoScale Corporation Common Stock Company Profile

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.